Nucleai Scores $33M for AI-Enabled Pathology Platform

Nucleai, maker of an AI-powered pathology platform that aims to predict a patient’s response to treatment, raised $33 million in Series B funding, per Mobi Helath News.

The round was led by Section 32 and Sanofi Ventures, with participation from existing investors including Debiopharm, Fosun RZ Capital, Vertex Ventures and Grove Ventures. The startup said the latest round brings its total raise to nearly $50 million.

Total
0
Shares
Related Posts
Read More

Validic Hauls in $12M

Kaiser Permanente Ventures led, and was joined by Arkin Digital Health, Green Park and Golf Ventures, Ziegler, Gore Range Capital, Greycroft Partners and SJF Ventures.